bluebird bio, Inc. (NASDAQ:BLUE) – Equities researchers at Leerink Swann decreased their Q3 2017 earnings per share (EPS) estimates for shares of bluebird bio in a note issued to investors on Wednesday. Leerink Swann analyst M. Schmidt now anticipates that the biotechnology company will earn ($1.79) per share for the quarter, down from their previous estimate of ($1.67). Leerink Swann also issued estimates for bluebird bio’s Q4 2017 earnings at ($1.86) EPS, FY2017 earnings at ($7.07) EPS, FY2018 earnings at ($7.29) EPS, FY2019 earnings at ($7.46) EPS and FY2020 earnings at ($5.10) EPS.
Other equities research analysts have also issued research reports about the stock. Cantor Fitzgerald set a $39.00 target price on shares of bluebird bio and gave the company a “sell” rating in a research note on Saturday, June 24th. Jefferies Group LLC reaffirmed a “buy” rating on shares of bluebird bio in a research note on Thursday, July 6th. Morgan Stanley lifted their target price on shares of bluebird bio from $103.00 to $105.00 and gave the company an “equal weight” rating in a research note on Monday. Sanford C. Bernstein assumed coverage on shares of bluebird bio in a research note on Thursday, July 27th. They set a “market perform” rating and a $109.00 target price on the stock. Finally, BMO Capital Markets reaffirmed a “buy” rating and set a $108.00 target price on shares of bluebird bio in a research note on Friday. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $100.66.
COPYRIGHT VIOLATION WARNING: “Q3 2017 EPS Estimates for bluebird bio, Inc. (BLUE) Cut by Leerink Swann” was posted by Markets Daily and is owned by of Markets Daily. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.themarketsdaily.com/2017/08/08/q3-2017-eps-estimates-for-bluebird-bio-inc-blue-cut-by-leerink-swann.html.
bluebird bio (NASDAQ:BLUE) opened at 98.65 on Monday. bluebird bio has a one year low of $37.05 and a one year high of $123.75. The firm’s market cap is $4.49 billion. The stock’s 50 day moving average is $102.86 and its 200 day moving average is $88.98.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.66) by $0.07. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The company had revenue of $16.70 million for the quarter, compared to analyst estimates of $6.29 million. During the same quarter in the prior year, the company posted ($1.59) EPS. bluebird bio’s revenue for the quarter was up 977.4% on a year-over-year basis.
Hedge funds and other institutional investors have recently modified their holdings of the company. Prudential Financial Inc. boosted its position in shares of bluebird bio by 4.0% in the second quarter. Prudential Financial Inc. now owns 3,882 shares of the biotechnology company’s stock valued at $408,000 after buying an additional 150 shares during the period. Usca Ria LLC boosted its position in shares of bluebird bio by 21.4% in the second quarter. Usca Ria LLC now owns 9,440 shares of the biotechnology company’s stock valued at $992,000 after buying an additional 1,665 shares during the period. Geneva Advisors LLC purchased a new position in shares of bluebird bio during the second quarter valued at about $337,000. Victory Capital Management Inc. boosted its position in shares of bluebird bio by 5.0% in the second quarter. Victory Capital Management Inc. now owns 983,271 shares of the biotechnology company’s stock valued at $103,292,000 after buying an additional 46,856 shares during the period. Finally, Marshall Wace North America L.P. boosted its position in shares of bluebird bio by 76.1% in the second quarter. Marshall Wace North America L.P. now owns 348,351 shares of the biotechnology company’s stock valued at $36,577,000 after buying an additional 150,484 shares during the period.
In other bluebird bio news, insider Eric Sullivan sold 861 shares of bluebird bio stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $93.83, for a total value of $80,787.63. Following the completion of the transaction, the insider now directly owns 5,924 shares of the company’s stock, valued at $555,848.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel Lynch sold 2,000 shares of bluebird bio stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $80.00, for a total transaction of $160,000.00. Following the completion of the transaction, the director now directly owns 3,400 shares of the company’s stock, valued at $272,000. The disclosure for this sale can be found here. Over the last three months, insiders have sold 77,106 shares of company stock valued at $8,018,895. 3.90% of the stock is currently owned by corporate insiders.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.